Literature DB >> 21750504

Chemotherapy: Standardizing the care of invasive bladder cancer.

Bernard H Bochner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21750504     DOI： 10.1038/nrclinonc.2011.109

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population.

Authors:  Deborah Schrag; Nandita Mitra; Feng Xu; Farhang Rabbani; Peter B Bach; Harry Herr; Colin B Begg
Journal:  Urology       Date:  2005-06       Impact factor: 2.649

2.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors: 
Journal:  Eur Urol       Date:  2005-04-25       Impact factor: 20.096

3.  Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy.

Authors:  Daniel Canter; Christopher Long; Alexander Kutikov; Elizabeth Plimack; Ismail Saad; Megan Oblaczynski; Fang Zhu; Rosalia Viterbo; David Y T Chen; Robert G Uzzo; Richard E Greenberg; Stephen A Boorjian
Journal:  BJU Int       Date:  2011-01       Impact factor: 5.588

4.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.

Authors: 
Journal:  Lancet       Date:  1999-08-14       Impact factor: 79.321

5.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

Authors:  Gareth Griffiths; Reginald Hall; Richard Sylvester; Derek Raghavan; Mahesh K B Parmar
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

6.  Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

Authors:  Bernard H Bochner; Michael W Kattan; Kinjal C Vora
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

7.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

8.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

9.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

Authors:  Kevin A David; Matthew I Milowsky; Jamie Ritchey; Peter R Carroll; David M Nanus
Journal:  J Urol       Date:  2007-06-11       Impact factor: 7.450
  9 in total
  1 in total

1.  A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer.

Authors:  S A Hussain; D H Palmer; B Lloyd; S I Collins; D Barton; J Ansari; N D James
Journal:  Oncol Lett       Date:  2012-01-12       Impact factor: 2.967
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.